Pipeline
With multiple clinical and preclinical assets in development, our growing product pipeline is bringing RNA Cell Therapy to autoimmune indications.
Myasthenia gravis
Descartes-08
SLE, other AAAD
Descartes-08
AAAD, myeloma
Descartes-15
AAAD
Descartes-33
Undisclosed
Undisclosed
AAAD: autoantibody-associated autoimmune diseases
SLE: Systemic Lupus Erythematosus
rMSC: Mesenchymal Stem Cells transfected with mRNA
LN: Lymph node
- rCAR-T programs (autologous)
- Allogenic programs
- In vivo LN transfection programs
Autoimmune
Myasthenia Gravis
Generalized myasthenia gravis (gMG) is a debilitating autoimmune disease affecting over 60,000 people in the U.S. Treatment of gMG requires the chronic use of toxic immunosuppressants.
DESCARTES-08, Cartesian’s clinical-stage lead product candidate, is the first RNA CAR T-cell (rCAR-T) therapy for autoimmune diseases. DESCARTES-08 contains killer T-cells designed to hunt down pathogenic plasma cells that secrete autoantibodies.
In a Phase 2a study, Descartes-08 was observed to be safe and well-tolerated, and to induce deep and durable responses in patients with gMG.
We are currently enrolling patients with gMG in a Phase 2b randomized controlled trial (RCT).